Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04809285 · ClinicalTrials.gov registry record · NA
Use of the Guardian™ Connect System With Smart Connected Devices
A NA study, sponsored by Medtronic MiniMed.
- Completed
- Registry status
- NA
- Development phase
- 217
- Enrollment target
NCT04809285: Completed NA study, sponsored by Medtronic MiniMed.
NCT04809285 is a NA study that has completed, run by Medtronic MiniMed. The registered enrollment target is 217 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04809285, a NA study, has completed, sponsored by Medtronic MiniMed.
- COMPLETED
- Registry status
- NA
- Development phase
- 217 participants
- Enrollment target
Study Summary
The purpose of this study is to collect sensor, insulin, sleep, activity and food/meal data for a minimum of 90 days of device wear (Phase 1) and up to a maximum of 9 months of device wear (Phase 2) with optional insulin injection video capture and/or menstrual cycle tracking and/or cardiac monitoring in subjects with insulin requiring diabetes 2-80 years of age.
Interventions
- DEVICE Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2021-04-06 |
| Est. Completion | 2023-09-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04809285
The ClinicalTrials.gov registry entry for NCT04809285 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic MiniMed, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app is the first listed.
NCT04809285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04809285 about?
NCT04809285 is a clinical study titled "Use of the Guardian™ Connect System With Smart Connected Devices". The purpose of this study is to collect sensor, insulin, sleep, activity and food/meal data for a minimum of 90 days of device wear (Phase 1) and up to a maximum of 9 months of device wear (Phase 2) with optional insulin injection video capture and/or menstrual cycle tracking and/or cardiac monitori...
What is the current status of trial NCT04809285?
This trial is currently completed. It is a NA study. The enrollment target is 217 participants. The study started on 2021-04-06. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT04809285?
The interventions under investigation include: Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app (DEVICE).
Who is sponsoring clinical trial NCT04809285?
This trial is sponsored by Medtronic MiniMed, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.